Werewolf Therapeutics, Inc. (HOWL) Stock Analysis
A live, multi-source view of Werewolf Therapeutics, Inc. (HOWL): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Werewolf Therapeutics, Inc.
Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; WTX-921, a conditionally activated IL-10 INDUKINE molecule for the treatment of inflammatory bowel disease and potentially other inflammatory diseases; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer.
Sector: Healthcare · Industry: Biotechnology · United States · 39 employees · werewolftx.com
Key statistics · as of 2026-09-06
As of 2026-09-06, Werewolf Therapeutics, Inc. (HOWL) had a market capitalization of $47.0M (forward -1.6) and a beta of 0.51; the shares traded in a 52-week range of $0.27 – $2.38 (-27.4% over the year).
- Market cap
- $47.0M
- Enterprise value
- $25.0M
- Forward P/E
- -1.6
- Price / book
- 2.88
- EPS (trailing)
- $-0.73
- EPS (forward)
- $-0.59
- Payout ratio
- 0.0%
- 52-week range
- $0.27 – $2.38
- 52-week change
- -27.4%
- Beta
- 0.51
- Average volume
- 7.0M
- Shares outstanding
- 48.6M
- Short % of float
- 2.66%
- Profit margin
- -164.8%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-10
In RapidTradeView’s 2026-09-10 scan of the US universe, Werewolf Therapeutics, Inc. (HOWL) last closed at $0.97 (the last completed close before that scan).
Technicals at the scan: RSI 75 (overbought territory), price +27.0% versus its 20-day average, 20-day versus 50-day average spread +43.4%, MACD histogram 0.01.
Sentiment inputs: StockTwits 100% bullish; analyst consensus score 75/100.
Next scheduled company event: in 50 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
RapidTradeView has recorded no Congress or insider filing for HOWL in the last 90 days. Coverage of House, Senate and SEC Form 4 filings began in July 2026, and insider sells are tracked for universe tickers only, so this is our record, not a guarantee that nothing was filed. Who is trading what
RapidTradeView pick record
HOWL has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Werewolf Therapeutics, Inc. (HOWL) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell HOWL.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.